Maharashtra's egg-donation racket, and the question India's fertility industry keeps dodging

On 28 June 2026, The Indian Express published an investigation that ought to make New Delhi uncomfortable. A woman in Maharashtra reportedly donated her eggs forty-five times across multiple clinics — a number so far outside any reasonable medical-safety framework that the story is less about one donor than about an industry that let it happen. The reporting describes scarred ovaries, repeat hormonal stimulation, and clinics that treated recruitment paperwork as a formality rather than a safeguard.

The story lands at a moment when India is still drafting the rules meant to govern exactly this corner of medicine. The Assisted Reproductive Technology (Regulation) Act, passed in 2021, was supposed to bring order to a sector that had grown faster than its oversight. On the evidence of one woman and the clinics that cycled her through, the law on paper has not yet become enforcement on the ground.

What The Indian Express actually reports

The piece centres on a single donor who, the paper says, gave eggs forty-five times — sometimes at multiple centres within a single cycle of months, in conditions inconsistent with the safety ceilings the Act sets. The donation was reportedly paid for, though specific compensation figures cited in investigative reporting of this kind are not spelled out in the publicly available framing. The reporting describes a pipeline: agents recruiting donors, clinics administering stimulation drugs, repeat procedures that risk ovarian hyperstimulation syndrome and long-term fertility damage. The Indian Express is an established Indian wire with a strong health-and-policy desk; its account fits a pattern documented across the country over the past decade, where ART clinics proliferated in private markets while the regulator lacked inspectors and the registry lagged.

What the published material does not specify — and the article should be read on its own terms — is the total number of clinics implicated, the chain of ownership, and whether any of them have been prosecuted under the Act. Those gaps matter. They are also the gaps Maharashtra's public-health authorities will be expected to fill, or explain why they cannot.

Why enforcement, not legislation, is the binding constraint

The temptation, when an investigative story like this surfaces, is to call for a new law. India already has the legislation in place: the ART Act of 2021 was explicitly designed to limit the number of times a woman can donate, mandate registration of clinics and banks, and compel the maintenance of donor records that would make a forty-fifth donation impossible on paper. The question is not whether the rule exists but who is checking.

The structural problem is familiar across Indian health regulation: a small inspectorate, a vast private sector, and a registry that takes years to populate. Clinics that want to behave badly have an obvious business model — recruit donors cheaply, cycle them quickly, and treat the registration line as a marketing expense rather than a compliance line. Until the state council set up under the Act has the staff, the data systems, and the political cover to act on a tip, the law will continue to function as a deterrent mostly to clinics that were not going to misbehave in the first place.

The Global South framing, taken seriously

The standard Western framing of stories like this treats India's fertility sector as a cautionary tale about unregulated markets — the implication being that a properly regulated industry would not produce a forty-fifth donation. That framing flatters the assumption that Western fertility markets are themselves orderly, and it understates what Indian ART has actually delivered: cycles at a fraction of US or UK cost, capacity that has made cross-border care feasible for patients from Europe, East Asia, and the Gulf, and a clinical workforce that trains at volume.

There is a structural point underneath the moral one. Where fertility treatment is treated as a luxury good — as it largely is in the United States — the same donor-protection problems are dispersed across smaller patient populations and softer reporting. Where it is treated as a high-volume service industry — as it has become in parts of India, and as commercial surrogacy was before the 2021 Act narrowed it — the failure modes are louder and easier to investigate. Forty-five donations in Maharashtra is not a uniquely Indian failure; it is a louder version of a failure that quieter markets also tolerate. Indian regulators should answer for it. Western readers should resist the comfort of pretending their own clinics never cut corners.

What has to happen next, and what might not

The credible next move from Maharashtra's health department is an audit of clinics named or implicated in the reporting, followed by either prosecution under the ART Act or a public explanation of why prosecution was not possible. The credible national move is for the National Medical Commission and the ART supervisory bodies to publish, for the first time, the size of the registered donor workforce, the average number of donations per registered donor, and the outcomes of inspections over the past three years. If those numbers look healthy, they will rebut the investigation. If they do not, they will confirm it.

What may not happen is movement on the underlying recruitment economics. As long as donor compensation in India is set far below the cost of the procedure and far below the prices paid by recipient couples abroad, the market will continue to produce donors who are over-extended by need and clinics that are over-extended by volume. Closing that gap requires either raising donor pay — politically difficult — or shrinking the legal market — commercially difficult. Neither will happen in a news cycle. Both are the actual story this investigation is trying to surface.

How Monexus framed this vs the wire: where most coverage treats the Indian Express investigation as a one-off scandal, this piece reads it as an enforcement failure inside an already-passed regulatory framework — and pushes back on the Western reflex to read Indian health-market failures as evidence of uniquely Indian disorder.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://en.wikipedia.org/wiki/Assisted_Reproductive_Technology_(Regulation)_Act,_2021